RT Journal Article
SR Electronic
T1 Comparison of Mental Health Symptom Changes from pre-COVID-19 to COVID-19 by Sex or Gender: A Systematic Review and Meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.28.21259384
DO 10.1101/2021.06.28.21259384
A1 Santo, Tiffany Dal
A1 Sun, Ying
A1 Wu, Yin
A1 He, Chen
A1 Wang, Yutong
A1 Jiang, Xiaowen
A1 Li, Kexin
A1 Bonardi, Olivia
A1 Krishnan, Ankur
A1 Boruff, Jill T.
A1 Rice, Danielle B.
A1 Markham, Sarah
A1 Levis, Brooke
A1 Azar, Marleine
A1 Neupane, Dipika
A1 Tasleem, Amina
A1 Yao, Anneke
A1 Thombs-Vite, Ian
A1 Agic, Branka
A1 Fahim, Christine
A1 Martin, Michael S.
A1 Sockalingam, Sanjeev
A1 Turecki, Gustavo
A1 Benedetti, Andrea
A1 Thombs, Brett D.
YR 2022
UL http://medrxiv.org/content/early/2022/02/23/2021.06.28.21259384.abstract
AB Importance Women and gender-diverse individuals have faced disproportionate socioeconomic burden during COVID-19. There have been reports that this has translated into greater negative changes in mental health, but this has been based on cross-sectional research that has not accounted for pre-COVID-19 differences.Objective To compare mental health symptom changes since pre-COVID-19 by sex or gender.Data Sources MEDLINE, PsycINFO, CINAHL, EMBASE, Web of Science, China National Knowledge Infrastructure, Wanfang, medRxiv, and Open Science Framework (December 31, 2019 to August 30, 2021).Study Selection Eligible studies compared mental health symptom changes from pre-COVID-19 to COVID-19 by sex or gender.Data Extraction and Synthesis Data was extracted by a single reviewer with validation by a second reviewer. Adequacy of study methods and reporting was assessed using an adapted version of the Joanna Briggs Institute Checklist for Prevalence Studies. A restricted maximum-likelihood random-effects meta-analyses was conducted.Main Outcomes and Measures Anxiety symptoms, depression symptoms, general mental health, and stress measured continuously or dichotomously.Results 12 studies (10 unique cohorts) were included. All compared females or women to males or men; none included gender-diverse individuals. Continuous symptom change differences were not statistically significant for depression (standardized mean difference [SMD]= 0.12, 95% CI -0.09 to 0.33; 4 studies, 4,475 participants; I2=69.0%) and stress (SMD= - 0.10, 95% CI -0.21 to 0.01; 4 studies, 1,533 participants; I2=0.0%), but anxiety (SMD= 0.15, 95% CI 0.07 to 0.22; 4 studies, 4,344 participants; I2=3.0%) and general mental health (SMD= 0.15, 95% CI 0.12 to 0.18; 3 studies, 15,692 participants; I2=0.0%) worsened more among females or women than males or men during COVID-19. There were no significant differences in changes in proportion above a cut-off: anxiety (difference= -0.05, 95% CI -0.20 to 0.11; 1 study, 217 participants), depression (difference= 0.12, 95% CI -0.03 to 0.28; 1 study, 217 participants), general mental health (difference= -0.03, 95% CI -0.09 to 0.04; 3 studies, 18,985 participants; I2=94.0%), stress (difference= 0.04, 95% CI -0.10 to 0.17; 1 study, 217 participants).Conclusion and Relevance Mental health outcomes did not differ or were worse by amounts below thresholds for clinical significance for women compared to men.Registration PROSPERO (CRD42020179703).Question Did mental health symptoms worsen more for females or women than males or men in COVID-19?Findings We reviewed almost 65,000 citations and identified 12 studies that provided data to directly compare mental health symptom changes from pre-COVID-19 to during COVID-19 for females or women versus males or men. Statistically significant, but small, sex- or gender-based differences were found in 2 of 8 mental health outcomes.Meaning Mental health changes among females or women were not significantly different from males or men for most outcomes, and differences that were identified were small and less than minimally important difference thresholds.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Canadian Institutes of Health Research (CMS-171703; GA4-177758; MS1-173070) and McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund (R2-42).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As this study was a systematic review of published results, it did not require ethical approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the study are available in the manuscript and its tables or online at https://www.depressd.ca/covid-19-mental-health. https://www.depressd.ca/covid-19-mental-health